This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

ASCP Corner

Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Lessons Learned

Sidney Zisook, MD; Krauz Ganadjian, MD; Christine Moutier, MD; Richard Prather, MD; and Sanjai Rao, MD

Published: July 31, 2008

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sequenced Treatment Alternatives toRelieve Depression (STAR*D), the largestprospective, randomized antidepressanttreatment trial to date in outpatients withmajor depressive disorder (MDD) recruitedfrom real-world clinical settings, enrolling4011 outpatients aged 18 to 75 years withnonpsychotic MDD. Designed to determinewhich treatments are most effective afternonremission or intolerance to an initial selectiveserotonin reuptake inhibitor (SSRI),or to any of a series of subsequent randomizedtreatments, STAR*D was conductedin 18 primary and 23 psychiatric care settingsacross the United States. This reviewsummarizes unique features of the study,initial remission rates and associated participantcharacteristics, remission rates forsubsequent treatment steps, relapse ratesduring follow-up, and clinical implications.’ ‹

Volume: 69

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...